Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$4.98 USD
+0.29 (6.18%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.98 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.98 USD
+0.29 (6.18%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.98 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum D VGM
Zacks News
Will Ironwood Suffer From Dependence on Linzess' Progress?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.
Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise
by Zacks Equity Research
Ironwood (IRWD) beats on both earnings and sales in the fourth quarter. Shares up.
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 88.24% and 50.70%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
by Zacks Equity Research
Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
by Zacks Equity Research
Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Ironwood Commences Phase I Study on IW-6463 for CNS Disorders
by Zacks Equity Research
Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff
by Zacks Equity Research
Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Ironwood/Allergan Settle Linzess Patent Litigation With Mylan
by Zacks Equity Research
Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.
Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.
Ironwood Pharmaceuticals (IRWD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -171.43% and -28.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Allergan (AGN) beats third-quarter estimates for earnings and sales and raises its full-year guidance for both the metrics. Botox remains the primary sales driver.
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Pharmaceuticals (IRWD) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.
Ironwood Stock Up, Heart Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
Why Is Ironwood (IRWD) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood's Linzess Gets Approval in Japan for New Indication
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.
Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
Ironwood Pharmaceuticals (IRWD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -47.37% and -9.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Begins New Phase III Study to Expand Linzess Label
by Zacks Equity Research
Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.